Zobrazeno 1 - 10
of 21
pro vyhledávání: '"M. H. Huls"'
Autor:
Saul J. Karpen, M. H. Huls, Cliona M. Rooney, T.R. Lee, Sarah E. Goodpastor, John A. Goss, Samuel Wyllie, Neal R. Barshes
Publikováno v:
Transplant Infectious Disease. 8:108-112
Background. Polymorphisms of the solute carrier family 11 member 1 (Slc11a1) gene have previously been associated with susceptibility to infectious disease, anti-tumor defenses, and autoimmune diseases. We postulated that polymorphisms of the gene ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e033c8f59630d288a5ad1050c0bde1dc
https://doi.org/10.1111/j.1399-3062.2006.00139.x
https://doi.org/10.1111/j.1399-3062.2006.00139.x
Autor:
M. H. Huls, Helen E. Heslop, Adrian P. Gee, G.D. Myers, Catherine M. Bollard, Uluhan Sili, Ann M. Leen, Cliona M. Rooney
Publikováno v:
Annals of the New York Academy of Sciences. 1062:104-115
Human adenoviruses are ubiquitous lytic DNA viruses that can be divided into 51 different serotypes, grouped from A to F on the basis of genome size, composition, homology, and organization. Adenovirus infections, although frequent, are rarely fatal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21829f80e2a4bed7a1da5af4e146d3d5
https://doi.org/10.1196/annals.1358.013
https://doi.org/10.1196/annals.1358.013
Autor:
Rana A. K. Singh, M. H. Huls, David M. Spencer, Brent A. Hanks, Jianghong Jiang, Weitao Song, Kevin M. Slawin, Michael A. Barry
Publikováno v:
Nature Medicine. 11:130-137
Modest clinical outcomes of dendritic-cell (DC) vaccine trials call for the refinement of DC vaccine design. Although many potential antigens have been identified, development of methods to enhance antigen presentation by DCs has lagged. We have engi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::496b120326e8b5f90d147fe351db4fc2
https://doi.org/10.1038/nm1183
https://doi.org/10.1038/nm1183
Autor:
Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard, Karin Straathof, Stephen Gottschalk, M. H. Huls, Malcolm K. Brenner
Publikováno v:
Vox Sanguinis. 87:230-234
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fdc5668e1f5144a6040031168385cd3
https://doi.org/10.1111/j.1741-6892.2004.00494.x
https://doi.org/10.1111/j.1741-6892.2004.00494.x
Autor:
Benedikt Gahn, Stephane Vigouroux, Helen E. Heslop, M. H. Huls, Cliona M. Rooney, Uluhan Sili, Hans Joachim Wagner, W. Xie, Malcolm K. Brenner, Dario A. A. Vignali
Publikováno v:
Cytotherapy. 5:231-240
Background EBV-associated malignancies with a Type II latency gene expression pattern, such as EBV-positive HD, or nasopharyngeal carcinoma, frequently express the EBV latency Ag LMP2a. Hence, they provide a potential target for adoptive immunotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2de6f8d29768df1f931bb9f3cc5c094
https://doi.org/10.1080/14653240310001262
https://doi.org/10.1080/14653240310001262
Autor:
Amer Najjar, Lenka V. Hurton, Partow Kebriaei, Sourindra Maiti, Laurence J.N. Cooper, M. H. Huls, Tiejuan Mi, Shihuang Su, Aaron F. Orozco, Harjeet Singh, Kirsten Switzer, Richard E. Champlin, Leo G. Flores
Publikováno v:
Blood. 128:2807-2807
T cells are genetically modified ex vivo to express chimeric antigen receptors (CARs) for in vivo clinical applications. CAR-modified T cells have demonstrated redirected specificity and, in several clinical trials, potent anti-tumor activity. Manufa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c390d11808125692badada72bd35d07c
https://doi.org/10.1182/blood.v128.22.2807.2807
https://doi.org/10.1182/blood.v128.22.2807.2807
Autor:
Partow Kebriaei, Krina K. Patel, Richard E. Champlin, Harjeet Singh, Muzaffar H. Qazilbash, Laurence J.N. Cooper, M. H. Huls, Lenka V. Hurton, Simon Olivares
Publikováno v:
Blood. 128:3366-3366
Adoptive transfer of T cells expressing chimeric antigen receptor (CAR) has demonstrated clinical effectiveness in early phase clinical trials, with persistence of effector cells typically leading to improved outcomes. Most CARs directly dock with ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dc9e5d6d57fff55567b340319d6488b
https://doi.org/10.1182/blood.v128.22.3366.3366
https://doi.org/10.1182/blood.v128.22.3366.3366
Autor:
Pappanaicken R Kumar, Dimitrios P. Kontoyiannis, Richard E. Champlin, Laurence J.N. Cooper, Matthew J. Figliola, N. Kaltz, Priti Tewari, Anne Richter, Sourindra Maiti, M. H. Huls
Publikováno v:
Cytotherapy. 18:S22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe978cc41d74f82f80d24de5e4cb1b30
https://doi.org/10.1016/j.jcyt.2016.03.061
https://doi.org/10.1016/j.jcyt.2016.03.061
Autor:
Enli Liu, Heidi V. Russell, C.M. Rooney, Heidi L. Weiss, M.K. Brenner, Martin Pule, Adrian P. Gee, Chrystal U. Louis, Gianpietro Dotti, Claudia Rossig, M. H. Huls, Barbara Savoldo, Helen E. Heslop, Zhuyong Mei, Eric Yvon, G.D. Myers
Publikováno v:
Biology of Blood and Marrow Transplantation. 15(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c5509d67744a1334fd4a748bd23313
Autor:
Helen E. Heslop, M. H. Huls, Malcolm K. Brenner, Cliona M. Rooney, Stephen Gottschalk, Catherine M. Bollard
Publikováno v:
Ernst Schering Research Foundation Workshop ISBN: 9783540220930
At present, CTL are being used only in patients with advanced relapsed malignancies. As their safety and efficacy becomes better established we may expect their introduction earlier in the course of therapy where they may reduce the short- and long-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b15d5c0b59a462cdeb8a7445cf416cce
https://doi.org/10.1007/3-540-26843-x_8
https://doi.org/10.1007/3-540-26843-x_8
